Cancer Therapy Using Antiparasitic Medications Guided by Acupuncture Meridian Assessment: A Case Series of Six Patients

Frederick Tim Guilford, MD; Simon Yu, MD

Abstract

Background: Cancer cells exhibit metabolic reprogramming often driven by aberrant Wnt/β-catenin signaling. Recent evidence suggests antiparasitic drugs can inhibit this pathway. Acupuncture Meridian Assessment (AMA), a modification of electroacupuncture according to Voll, measures electrical conductance at acupuncture points to guide therapeutic interventions.

Objective: To evaluate clinical outcomes of AMA-guided antiparasitic and antifungal therapy in patients with advanced cancer.

Methods: Six patients with stage IV cancers (breast, lung, prostate, glioblastoma, and multiple myeloma) underwent AMA evaluation between 2011 and 2022. Treatment protocols included combinations of ivermectin, mebendazole, praziquantel, niclosamide, and antifungals, selected based on AMA readings. Primary outcomes were overall survival and disease progression. Dental infections were addressed concurrently.

Results: All six patients demonstrated prolonged survival, exceeding the expected conventional prognosis. The breast cancer patient achieved complete remission (30+ months disease-free). The multiple myeloma patient has been surviving 14 years with normalized biomarkers. The lung cancer patient has been surviving 10 years post-diagnosis with negative imaging. Both glioblastoma patients showed tumor regression with extended survival, although one glioblastoma patient died from a fall with head injury in 2025 after submitting this article. The prostate cancer patient is surviving and has achieved a PSA reduction from 32 to 0.3. No serious adverse events were reported.

Conclusions: AMA-guided antiparasitic therapy showed promising outcomes in this small case series. These preliminary results warrant further study to evaluate the efficacy and safety of this integrative approach.

Keywords: electroacupuncture according to Voll, acupuncture meridian assessment, Wnt/β-catenin pathway, repurposed drugs, antiparasitic therapy, integrative oncology

Frederick Tim Guilford, MD, Science Officer, Your Energy Systems, Palo Alto, CA, USA. Simon Yu, MD, works in the private practice of medicine in a practice titled Prevention and Healing in St. Louis, MO, USA.

Corresponding author: Frederick Tim Guilford, MD  

E-mail: drg@readisorb.com  

Introduction

Cancer metabolism has been a focus of research since Otto Warburg’s 1924 discovery of altered glucose utilization in tumor cells. Contemporary understanding reveals cancer metabolism to be highly heterogeneous, with many variations resulting from aberrant Wnt/β-catenin signaling, which is a pathway crucial for normal tissue development, and which becomes dysregulated in malignancy.^1,2

The Wnt pathway drives metabolic reprogramming, promoting glycolysis, glutaminolysis, and supporting cancer stem cell survival.^3,4 Aberrant Wnt activation is implicated in multiple cancer types, contributing to therapeutic resistance through mechanisms including enhanced oxidative-stress management and tumor microenvironment manipulation.^5-8

Current cancer therapeutics face significant challenges, particularly in advanced disease where conventional treatments often fail to provide durable responses.^9-11 The emergence of drug repurposing offers new therapeutic possibilities, with antiparasitic agents showing unexpected anti-cancer properties through Wnt pathway inhibition.^12-16

Acupuncture Meridian Assessment (AMA), developed by Dr. Simon Yu as a modification of Electroacupuncture According to Voll (EAV), measures electrical conductance at specific acupuncture points to assess organ function and guide therapeutic selection.^17,18 EAV displays clinical utility in various diagnostic applications, with studies demonstrating correlations between electrical readings and pathological conditions.^18-20,22

This case series evaluates the clinical outcomes of AMA-guided antiparasitic and antifungal therapy in six patients with advanced cancer, hypothesizing this integrative approach could therapeutically benefit through Wnt pathway modulation and address underlying microbial contributions to cancer progression.

Methods

Study Design

This retrospective case series analyzes six patients with advanced cancer treated with AMA-guided antiparasitic therapy between 2011-2022 at a single integrative medicine practice.

Patient Selection

Inclusion Criteria. (1) Histologically confirmed advanced cancer (stage III-IV); (2) Life expectancy <2 years based on conventional prognosis; (3) Completion of or refusal of standard oncological treatment; (4) Informed consent for alternative treatment approach.

Exclusion Criteria. (1) Active conventional cancer treatment during the study period; (2) Severe hepatic or renal impairment; (3) Pregnancy or lactation.

Acupuncture Meridian Assessment Protocol

Equipment. Studies were conducted using a modern version of the original EAV device, a commercially available MORA device (MED-Tronik, Germany, measuring electrical conductance at acupuncture points; scale 0-100, normal range 45-55).^21,23

Procedure. The procedure detailed below was followed:

A diagram of the testing setup is shown in Figure 1.²³

Figure 1. A diagram of the testing set up is shown

Patient was positioned comfortably with skin cleaned using alcohol wipes.

Baseline measurements taken at 40 standard acupuncture points representing major organ systems^23,24 (Figure 1).

Points showing abnormal readings (indicator drop <45 or >65) were identified.

Medication testing was performed by introducing test substances into the circuit as described by Voll,^17,23 (Figure 1).

Substances normalizing aberrant readings were selected for the therapeutic protocol.

Standardization Measures. Same operator (S.Y.) performed all assessments; Consistent environmental conditions (temperature 68-72°F, humidity <60%) were maintained; Calibration checks were performed daily; Repeat measurements were taken to ensure reproducibility.²³

Treatment Protocols

A combination of the following medications and therapies was chosen using the AMA testing as a guide.

Antiparasitic Agents. (i) Ivermectin: 12-24 mg three times daily, 3 weeks on/1 week off;^13,14,25 (ii) Mebendazole: 100 mg three times daily, 3 weeks on/1 week off;^26,27,28 (iii) Praziquantel: 600 mg three times daily, 3 weeks on/1 week off;^29,30 (iv) Niclosamide: 500-1000 mg three times daily, 3 weeks on/1 week off;^12,15,31 (v) Pyrantel pamoate: 725 mg three times daily, 3 weeks on/1 week off.

Antifungal Agents: Antifungal agents were utilized when the medications were found to restore the meridian reading to normal in each individual. (i) Itraconazole: 100 mg three times daily;^32-36 (ii) Fluconazole: 100 mg three times daily;^37,38 (iii) Nystatin: 500 000 U three times daily.³⁹

Supportive Therapies. These agents were used when medications were found to restore the meridian reading to normal in each individual, so the usage varied as guided by the findings. (i) Doxycycline: 100 mg three times daily (when indicated);^40-42 (ii) Tinidazole: 250-500 mg three times daily (when indicated); (iii) Azithromycin: 500 mg three times daily (when indicated);⁴³ (iv) Doxycycline, Azithromycin, and Vitamin C (DAV).⁴²

Dental Protocol. All patients underwent a comprehensive dental evaluation with a biological dentist. Infected teeth, root canals, and cavitation sites were addressed through extraction or surgical debridement as clinically indicated.^44-50

Outcome Measures

Primary Outcomes. (i) Overall survival from treatment initiation; (ii) Progression-free survival; (iii) Radiographic response (RECIST 1.1 criteria when applicable).⁵¹

Secondary Outcomes. (i) Biomarker changes (PSA, tumor markers, kappa light chains); (ii) Performance status (ECOG scale): The ECOG Performance Status Scale, or ECOG-PS, is a 0–5 point system used in oncology to evaluate a patient’s ability to perform daily activities;⁵² (iii) Quality of life assessment using the short form health assessment;⁵³ (iv) Adverse events (CTCAE v5.0) Common Terminology Criteria for Adverse Events (CTCAE), any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment.⁵⁴

Data Collection and Analysis

Patient data collected retrospectively from medical records, including: (i) Demographics and cancer characteristics; (ii) Treatment protocols and duration; (iii) Serial imaging and laboratory results; (iv) Adverse event documentation; (v) Survival data with a minimum of 12-month follow-up.

Statistical Analysis

Descriptive statistics were calculated for patient characteristics and outcomes. Kaplan-Meier analysis performed for survival data. Given the small sample size, formal statistical testing was not performed.

Ethical Considerations

All patients provided informed consent for treatment. This retrospective analysis was conducted in accordance with institutional guidelines for case series reporting. Patient identities were de-identified for publication.

Results

Patient Characteristics

Six patients with advanced cancers were treated between 2011 and 2022 (Table 1). Median age was 55 years (range: 46-75 years). All patients had stage IV disease except two with recurrent glioblastoma following standard therapy.

Table 1. Patient Demographics and Cancer Characteristics

AMA Findings

All patients demonstrated abnormal readings at multiple meridian points (ranging from 13 to 20 out of 40 points).²¹ (Hong 2016), Most common abnormalities involved: (i) Lymphatic system (6/6 patients); (ii) Liver/detoxification pathways (5/6 patients); (iii) Immune system markers (5/6 patients); (iv) Organ-specific points corresponding to primary tumor location (6/6 patients).

Medication testing consistently indicated the normalization of aberrant readings with antiparasitic and antifungal agents, guiding treatment selection as previously described.⁵⁵

Treatment Outcomes

Each patient (Table 1) was treated with medications normalizing the abnormal AMA readings. Tooth evaluation, as indicated by abnormal meridian testing, was recommended.

Case 1 – Breast Cancer. 46-year-old female with stage IV triple-negative breast cancer and metastases to sternum, lymph nodes, and lung. Following 60 days of combination therapy (ivermectin, doxycycline, tinidazole, pyrantel pamoate, praziquantel, nystatin) and dental work, the patient achieved a complete radiographic response. Remained disease-free at 30+ months follow-up.

Case 2 – Multiple Myeloma. 46-year-old female with stage IV multiple myeloma and bone metastases. Kappa light chain levels decreased from >4000 to 156 mg/L (near normal). Bone pain resolved within 2 years. Surviving 14 years post-diagnosis with continued treatment rotations that include Ozone Ultraviolet Blood Irradiation, intravenous vitamin C, and Insulin Potentiation Therapy (IPT).

Case 3 – Lung Cancer. 72-year-old male with stage IV Non-Small Cell Lung Cancer (NSCLC) and bone metastases. Initially inoperable, the tumor became resectable after treatment with ivermectin, praziquantel, nitazoxanide (Alinia), mebendazole, itraconazole, and fluconazole. Surgical pathology revealed coccidiomycosis infection within tumor. Ten consecutive positron emission tomography (PET) scans were negative over a 10-year follow-up.

Case 4 – Glioblastoma. 46-year-old male with recurrent glioblastoma post-standard therapy. Treatment included ivermectin 12 mg, mebendazole 100 mg, praziquantel 600 mg, azithromycin 500 mg, tinidazole 500 mg, and nystatin 500 000 IU, followed by doxycycline 100 mg, fluconazole 100 mg, itraconazole 100 mg, and 3-bromopyruvate. Tumor size decreased from approximaatly 2 cm. to minimal on 13-month follow-up imaging as seen in images on pp. 109-210⁵⁶

Case 5 – Glioblastoma. 64-year-old female with recurrent glioblastoma. AMA indicated 13 out of 40 meridians were out of balance. Treatment protocol: ivermectin 24 mg, mebendazole 100 mg, praziquantel 600 mg, niclosamide 1000 mg, tinidazole 250 mg (3 weeks on, 1 week off for 6 cycles), followed by nystatin 55 000 IU, fluconazole 100 mg, and itraconazole 100 mg. Reported as the only survivor among 12 patients in a concurrent medical experimental therapy group, in which the patient elected not to participate. Tumor undetectable on imaging with resolution of neurological symptoms at 4-year follow-up.

Case 6 – Prostate Cancer. 75-year-old male with stage IV prostate cancer, PSA 32 ng/mL. Treatment protocol: Ivermectin, chlorine dioxide, and fenbendazole. PSA decreased to 0.3 ng/mL with no evidence of metastatic disease.

Survival Analysis 

Median overall survival has not been reached with a median follow-up of 48 months (range 13-168 months). All six patients exceeded their expected prognosis based on conventional treatment outcomes:

Expected survival: 3-24 months

Actual survival: 13-168+ months (6/6 patients still alive)

Adverse Events

No serious adverse events (Grade 3-4 CTCAE) were reported. Mild gastrointestinal symptoms (Grade 1-2) occurred in 3/6 patients, which were managed with dose reduction or temporary treatment interruption. No treatment discontinuations due to toxicity occurred, consistent with the generally favorable safety profile of these repurposed agents.

Biomarker Responses

Objective biomarker improvements were documented in 4/6 patients with measurable markers: Multiple myeloma: Kappa light chains 4000→156 mg/L; Prostate cancer: PSA 32→0.3 ng/mL; and improved biomarker levels throughout the follow-up period; Glioblastoma cases: scans improved.

Discussion

This case series demonstrates prolonged survival in six patients with advanced cancers treated with AMA-guided antiparasitic therapy. All patients exceeded the expected survival (based on conventional prognosis), with several achieving complete or near-complete responses.

Proposed Mechanisms of Action

The clinical responses observed may result from multiple mechanisms:

Wnt Pathway Inhibition. Antiparasitic drugs used in this series have demonstrated Wnt/β-catenin pathway inhibition in preclinical studies. Ivermectin blocks β-catenin/TCF function,¹³ while niclosamide down-regulates multiple Wnt pathway components.^12,15 Benzimidazole compounds disrupt microtubules and reduce β-catenin nuclear transport.^26-28,57 Pyrvinium pamoate inhibits Wnt signaling and mitochondrial oxidative phosphorylation.^16,58

Microtubule Targeting. Several agents target microtubules, potentially disrupting cancer cell division and β-catenin signaling.^57,59 This mechanism may explain responses across different cancer types.

Metabolic Disruption. Several drugs may interfere with cancer cell metabolism through mitochondrial targeting,^40-42 and disruption of the “reverse Warburg effect” where cancer cells parasitize stromal cell metabolism.^60-63

Microbial Factors. The concurrent treatment of dental infections and potential systemic microbial burden may address the inflammatory drivers of cancer progression.^44,64-67 The surgical pathology from Case 3 supports this hypothesis by revealing a fungal infection within the tumor and may function in a similar manner to Fusobacterium nucleatum, an oral anaerobe rarely seen in a healthy lower GI tract but frequently found in colorectal cancer (CRC). Fusobacterium nucleatum pathogen is known to activate Wnt/β-catenin pathways, providing a biological mechanism for the infection’s impact.^68-72

The finding of coccidiomycosis in the tumor mass of Case 3 is an example of a microbe-related cancer, The fungus acts as an inflammatory provocateur. It doesn’t necessarily rewrite the cell’s code itself, but it creates a toxic, inflamed environment stimulating the cell’s signaling pathways (like Wnt) into an inflmmatory “overdrive” state conducive to cancer.^44,64-72

Oxidative Stress Modulation. Several agents increase reactive oxygen species production in cancer cells,^25,27,31 potentially overwhelming cancer cell antioxidant defenses while leaving normal cells protected.

Clinical Implications

These results suggest AMA-guided therapy may offer a systematic approach to treatment selection in integrative oncology. The method’s ability to guide medication selection based on individual patient responses represent a form of personalized medicine within complementary approaches, building on established EAV research.^17-22,24

The role of concurrent dental infection treatment deserves emphasis, as chronic oral infections have established links to systemic cancer risk,^44,67,73-75 and may contribute to treatment resistance through inflammatory mechanisms involving IL-6, TGF-β, and other cytokines.^76-84

Comparison to Literature

Limited published data exist on antiparasitic drugs in human cancer treatment. Our previous publication in 2019,⁵⁵ first described this approach, and subsequent research has supported the anti-cancer properties of these agents. The survival outcomes compare favorably to historical controls for similar advanced cancers, though direct comparison is limited by patient selection and concurrent treatments.

Preclinical studies support the mechanisms proposed: ivermectin inhibits Wnt/β-catenin and Akt/mTOR pathways,^13,14,25 Niclosamide targets multiple signaling pathways, including Wnt, NF-κB, and Notch,^15,31 and benzimidazoles disrupt microtubules while increasing oxidative stress,^26,27,28 and antifungal agents like itraconazole inhibit Hedgehog, Wnt, and PI3K/mTOR pathways.^{32,33,34,35,36}

Limitations

This study has several limitations:

Study Design: Retrospective case series without control group limits conclusions about the causality and efficacy.

Selection Bias: Patients self-selected for alternative treatment, potentially representing healthier or more motivated individuals.

Concurrent Treatments: All patients received multiple interventions including dental treatment, making it difficult to isolate effects of antiparasitic therapy.

Small Sample Size: Six patients provide insufficient power for statistical analysis or generalizability.

Outcome Assessment: Lack of standardized quality of life measures and formal response criteria for some cases.

AMA Validation: The AMA technique lacks independent validation and standardization across practitioners, though it builds on established EAV research.^{17,23,24,85,86}

Safety Considerations

While no serious adverse events occurred, the long-term safety of extended antiparasitic drug use in cancer patients requires systematic evaluation. Drug interactions, resistance patterns, and cumulative toxicities need investigation in larger cohorts. A veterinary antihelminthic once considered an adjuvant chemotherapeutic agent levamisole was not used as it was discontinued due to toxicity concerns.⁸⁷

Future Directions

These preliminary results warrant prospective clinical trials with appropriate control groups. Recommended next steps include:

Pilot Randomized Controlled Trial: Compare AMA-guided therapy to standard supportive care in advanced cancer patients.

AMA Validation Studies: Independent assessment of AMA reproducibility and correlation with clinical outcomes, building on existing EAV research.^19,21,23,24

Mechanistic Studies: Laboratory investigation of Wnt pathway inhibition and other proposed mechanisms in patient samples.

Safety Surveillance: Systematic collection of adverse events in larger patient cohorts.

Biomarker Development: Identification of predictive markers for treatment response, potentially including microbial profiling, given the dental infection findings.

Conclusions

This case series demonstrates promising clinical outcomes in six patients with advanced cancer treated with AMA-guided antiparasitic therapy. While limited by study design constraints, the consistent pattern of prolonged survival across different cancer types suggests potential therapeutic benefit, warranting further investigation.

The integration of diagnostic assessment (AMA), targeted therapy selection, and concurrent treatment of potential microbial contributors represents a novel approach to integrative cancer care. The mechanistic rationale is supported by extensive preclinical literature on Wnt pathway inhibition by antiparasitic drugs, and the role of chronic infections in cancer progression.

The remarkable responses observed, particularly the unusually prolonged survival warranting further investigation in advanced disease, highlight the potential for repurposed drugs in oncology while emphasizing the need for rigorous scientific evaluation of integrative approaches.

Funding

No external funding was received for this study.

Ethics approval and consent to participate

Individual patients gave their approval for publication, and no identifying information was used.

Competing Interests

Dr. S.Y. has no financial interest in the AMA diagnostic approach. The authors declare they have no competing interests.

Authors’ contributions

S.Y. obtained the information, and F.T.G. drafted the manuscript with support from S.Y.

Acknowledgements

The authors thank the patients who consented to share their treatment experiences and outcomes for this report. Consent for publication on file with S.Y. Availability of data and materials is the peoperty of S.Y.

References

1. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J. 2012;31(12):2670-2684. doi:10.1038/emboj.2012.146
2. Nusse R, Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169(6):985-999. doi:10.1016/j.cell.2017.05.016
3. Vallée A, Lecarpentier Y, Vallée JN. The Key Role of the WNT/β-Catenin Pathway in Metabolic Reprogramming in Cancers under Normoxic Conditions. Cancers (Basel). 2021;13(21):5557. doi:10.3390/cancers13215557
4. Leung RWH, Lee TKW. Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers (Basel). 2022;14(21):5468. doi:10.3390/cancers14215468
5. Sherwood V. WNT signaling: an emerging mediator of cancer cell metabolism? Mol Cell Biol. 2015;35(1):2-10. doi:10.1128/MCB.00992-14
6. Iqbal MJ, Kabeer A, Abbas Z, et al. Interplay of oxidative stress, cellular communication and signaling pathways in cancer. Cell Commun Signal. 2024;22(1):7. doi:10.1186/s12964-023-01398-5
7. El-Sahli S, Xie Y, Wang L, Liu S. Wnt Signaling in Cancer Metabolism and Immunity. Cancers (Basel). 2019;11(7):904. doi:10.3390/cancers11070904
8. Groenewald W, Lund AH, Gay DM. The Role of WNT Pathway Mutations in Cancer Development and an Overview of Therapeutic Options. Cells. 2023;12(7):990. doi:10.3390/cells12070990
9. NIH NCI. Cancer Stat Facts: Common Cancer Sites. NIH; 2025 [updated 2025 2025; cited 2025 Aug 8, 2025]. Accessed April 25, 2026. https://seer.cancer.gov/statfacts/html/common.html?utm_source=chatgpt.com
10. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-1380. doi:10.1056/NEJMra0802714
11. Zhang Z, Westover D, Tang Z, et al. Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer. J Transl Med. 2024;22(1):565. doi:10.1186/s12967-024-05380-8
12. Osada T, Chen M, Yang XY, et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011;71(12):4172-4182. doi:10.1158/0008-5472.CAN-10-3978
13. Melotti A, Mas C, Kuciak M, Lorente-Trigos A, Borges I, Ruiz i Altaba A. The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med. 2014;6(10):1263-1278. doi:10.15252/emmm.201404084
14. Jiang L, Sun YJ, Song XH, et al. Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway. Am J Cancer Res. 2022;12(10):4502-4519.
15. Pan JX, Ding K, Wang CY. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012;31(4):178-184. doi:10.5732/cjc.011.10290
16. Ahmed K, Shaw HV, Koval A, Katanaev VL. A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers. Cancers (Basel). 2016;8(7):66. doi:10.3390/cancers8070066
17. Voll R. The phenomenon of medicine testing in electro acupuncture according to voll. Am J Acupunct. 1980;8(2):97-104. Accessed April 25, 2026. https://www.academia.edu/20291376/Electroacupuncture_According_to_Voll_Historical_Background_and_Literature_Review
18. Djumaeva N, Akhundjanova G, Djumaeva L, Urunova D. Medicament testing on acupuncture points as a non-invasive diagnostic tool for determining the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection. Future J Pharm Sci. 2023;9(1):62. doi:10.1186/s43094-023-00514-z
19. Tseng YJ, Hu WL, Hung IL, Hsieh CJ, Hung YC. Electrodermal screening of biologically active points for upper gastrointestinal bleeding. Am J Chin Med. 2014;42(5):1111-1121. doi:10.1142/S0192415X14500694
20. Sullivan SG, Eggleston D, Martinoff J, Kroening R. Evoked electrical-conductivity on the lung acupuncture points in healthy-individuals and confirmed lung-cancer patients. Am J Acupunct. 1985;13(3):261-266. Accessed April 25, 2026. https://www.diagcenter.si/dokumenti/studije/eap-mora/EAP-MORA-Sullivan1985-LungCancer.pdf
21. Hong HG. Electrodermal Measurement of Acupuncture Points May Be a Diagnostic Tool for Respiratory Conditions: A Retrospective Chart Review. Med Acupunct. 2016;28(3):137-147. doi:10.1089/acu.2016.1177
22. Djumaeva N, Akhundjanova G, Djumaeva L, Urunova D. Medicament Testing in the Diagnosis of Long COVID Syndrome. OBM Integrative and Complementary Medicine. 2024;09(01):010. doi:10.21926/obm.icm.2401010
23. Chen M, Chen Z, Liu Q, et al. Electrodermal Energy Wave at Acupuncture Points May Be a Biomarker of Aging. J Dermatol Dermatol Surg. 2018;22(2):60-63. doi:10.4103/jdds.jdds_21_18
24. Sancier KM. The effect of qigong on therapeutic balancing measured by Electroacupuncture According to Voll (EAV): a preliminary study. Acupunct Electrother Res. 1994;19(2-3):119-127. doi:10.3727/036012994816357295
25. Liu Y, Fang S, Sun Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2016;480(3):415-421. doi:10.1016/j.bbrc.2016.10.064
26. Chu SW, Badar S, Morris DL, Pourgholami MH. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 2009;29(10):3791-3796.
27. Kim U, Shin C, Kim CY, et al. Albendazole exerts antiproliferative effects on prostate cancer cells by inducing reactive oxygen species generation. Oncol Lett. 2021;21(5):395. doi:10.3892/ol.2021.12656
28. Zhang QL, Lian DD, Zhu MJ, et al. Antitumor Effect of Albendazole on Cutaneous Squamous Cell Carcinoma (SCC) Cells. BioMed Res Int. 2019;2019:3689517. doi:10.1155/2019/2076579
29. Pfab C, Schnobrich L, Eldnasoury S, Gessner A, El-Najjar N. Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know? Cancers (Basel). 2021;13(13):3193. doi:10.3390/cancers13133193
30. Wu ZH, Lu MK, Hu LY, Li X. Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. PLoS One. 2012;7(12):e51721. doi:10.1371/journal.pone.0051721
31. Lu L, Dong J, Wang L, et al. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene. 2018;37(39):5292-5304. doi:10.1038/s41388-018-0340-y
32. Liang G, Liu M, Wang Q, et al. Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways. Oncotarget. 2017;8(17):28510-28525. doi:10.18632/oncotarget.15324
33. Wang W, Dong X, Liu Y, et al. Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways. Biomed Pharmacother. 2020;131:110661. doi:10.1016/j.biopha.2020.110661
34. Shen D, Xia Y, Fu Y, et al. Hedgehog pathway and cancer: A new area (Review). [Review]. Oncol Rep. 2024;52(3):116. doi:10.3892/or.2024.8775
35. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388-399. doi:10.1016/j.ccr.2010.02.027
36. Kulkarni AM, Gayam PKR, Baby BT, Aranjani JM. Epithelial-Mesenchymal Transition in Cancer: A Focus on Itraconazole, a Hedgehog Inhibitor. Biochim Biophys Acta Rev Cancer. 2025;1880(2):189279. doi:10.1016/j.bbcan.2025.189279
37. Weng N, Zhang Z, Tan Y, Zhang X, Wei X, Zhu Q. Repurposing antifungal drugs for cancer therapy. J Adv Res. 2023;48:259-273. doi:10.1016/j.jare.2022.08.018
38. Doheny D, Manore S, Sirkisoon SR, et al. An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1. Cancers (Basel). 2022;14(17):4256. doi:10.3390/cancers14174256
39. Sousa F, Nascimento C, Ferreira D, Reis S, Costa P. Reviving the interest in the versatile drug nystatin: A multitude of strategies to increase its potential as an effective and safe antifungal agent. Adv Drug Deliv Rev. 2023;199:114969. doi:10.1016/j.addr.2023.114969
40. Lamb R, Ozsvari B, Lisanti CL, et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget. 2015;6(7):4569-4584. doi:10.18632/oncotarget.3174
41. Scatena C, Roncella M, Di Paolo A, et al. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. Front Oncol. 2018;8:452. doi:10.3389/fonc.2018.00452
42. Fiorillo M, Tóth F, Sotgia F, Lisanti MP. Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). Aging (Albany NY). 2019;11(8):2202-2216. doi:10.18632/aging.101905
43. Takano N, Hiramoto M, Yamada Y, et al. Azithromycin, a potent autophagy inhibitor for cancer therapy, perturbs cytoskeletal protein dynamics. Br J Cancer. 2023;128(10):1838-1849. doi:10.1038/s41416-023-02210-4
44. Meyer MS, Joshipura K, Giovannucci E, Michaud DS. A review of the relationship between tooth loss, periodontal disease, and cancer. Cancer Causes Control. 2008;19(9):895-907. doi:10.1007/s10552-008-9163-4
45. Wei X, Pushalkar S, Estilo C, et al. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2012;18(6):602-612. doi:10.1111/j.1601-0825.2012.01916.x
46. Heselich A, Neff P, Śmieszek-Wilczewska J, Sader R, Ghanaati S. Introduction of a Semi-Quantitative Image-Based Analysis Tool for CBCT-Based Evaluation of Bone Regeneration in Tooth Extraction Sockets. Bioengineering (Basel). 2025;12(3):301. doi:10.3390/bioengineering12030301
47. Rothchild J. DNA analysis of root canal teeth and cavitation surgery of sockets utilizing ozone water irrigation: a pilot study [abstract]. Journal of Ozpne Therapy.2019;3(4):52. doi:10.7203/jo3t.3.4.2019.15532
48. Parirokh M, Zarifian A, Ghoddusi J. Choice of Treatment Plan Based on Root Canal Therapy versus Extraction and Implant Placement: A Mini Review. Iran Endod J. 2015;10(3):152-155. doi:10.7508/iej.2015.03.001
49. Conrad J, Retelsdorf J, Attia S, Dörfer C, Mekhemar M. German Dentists’ Preferences for the Treatment of Apical Periodontitis: A Cross-Sectional Survey. Int J Environ Res Public Health. 2020;17(20):7447. doi:10.3390/ijerph17207447
50. Durmazpınar PM, Kanmaz B, Buduneli N. Endo-Perio Lesions and Dentists’ Treatment Approach: A Survey. Med Sci Monit. 2024;30:e942544. doi:10.12659/MSM.942544
51. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
52. ECOG Performance Status. SEER Training Module. 2023. Accessed April 25, 2026. https://training.seer.cancer.gov/followup/dataset/ecog-performance-status.html
53. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483. doi:10.1097/00005650-199206000-00002
54. Common Terminology Criteria for Adverse Events (CTCAE). 2017 [updated 2017; cited]. Accessed April 25, 2026. https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5×7.pdf.
55. Guilford FT, Yu S. Antiparasitic and Antifungal Medications for Targeting Cancer Cells Literature Review and Case Studies. Altern Ther Health Med. 2019;25(4):26-31.
56. Yu S. Accidental Cure 3: AI Vs. Ancient Intelligence (Medical Acupuncture). Prevention and Healing, Inc; 2025:402.
57. Kumari A, Shriwas O, Sisodiya S, et al. Microtubule-targeting agents impair kinesin-2-dependent nuclear transport of β-catenin: evidence of inhibition of Wnt/β-catenin signaling as an important antitumor mechanism of microtubule-targeting agents. FASEB J. 2021;35(4):e21539. doi:10.1096/fj.202002594R
58. Schultz CW, Nevler A. Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug. Biomedicines. 2022;10(12):3249. doi:10.3390/biomedicines10123249
59. Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018;8(1):11926. doi:10.1038/s41598-018-30158-6
60. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al. Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle. 2011;10(11):1772-1783. doi:10.4161/cc.10.11.15659
61. Martinez-Outschoorn UE, Pestell RG, Howell A, et al. Energy transfer in “parasitic” cancer metabolism: mitochondria are the powerhouse and Achilles’ heel of tumor cells. Cell Cycle. 2011;10(24):4208-4216. doi:10.4161/cc.10.24.18487
62. Payen VL, Mina E, Van Hée VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab. 2020;33:48-66. doi:10.1016/j.molmet.2019.07.006
63. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle. 2010;9(16):3256-3276. doi:10.4161/cc.9.16.12553
64. Hansen JP, Ali WM, Sivadasan R, Rajeeve K. Bacteria-Cancer Interface: Awaiting the Perfect Storm. Pathogens. 2021;10(10):1321. doi:10.3390/pathogens10101321
65. Battaglia TW, Mimpen IL, Traets JJH, et al. A pan-cancer analysis of the microbiome in metastatic cancer. Cell. 2024;187(9):2324-2335.e19. doi:10.1016/j.cell.2024.03.021
66. Momen-Heravi F, Babic A, Tworoger SS, et al. Periodontal disease, tooth loss and colorectal cancer risk: Results from the Nurses’ Health Study. Int J Cancer. 2017;140(3):646-652. doi:10.1002/ijc.30486
67. Botelho J, Mascarenhas P, Viana J, et al. An umbrella review of the evidence linking oral health and systemic noncommunicable diseases. Nat Commun. 2022;13(1):7614. doi:10.1038/s41467-022-35337-8
68. Zepeda-Rivera M, Minot SS, Bouzek H, et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature. 2024;628(8007):424-432. doi:10.1038/s41586-024-07182-w
69. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195-206. doi:10.1016/j.chom.2013.07.012
70. Brennan CA, Garrett WS. Gut Microbiota, Inflammation, and Colorectal Cancer. Annu Rev Microbiol. 2016;70(1):395-411. doi:10.1146/annurev-micro-102215-095513
71. Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344-355. doi:10.1016/j.immuni.2015.01.010
72. Liu H, Yu Y, Dong A, Elsabahy M, Yang YW, Gao H. Emerging strategies for combating Fusobacterium nucleatumin colorectal cancer treatment: systematic review, improvements and future challenges. Exploration (Beijing). 2023;4(1):20230092. doi:10.1002/EXP.20230092
73. Virtanen E, Söder B, Andersson LC, Meurman JH, Söder PO. History of dental infections associates with cancer in periodontally healthy subjects: a 24-year follow-up study from sweden. J Cancer. 2014;5(2):79-85. doi:10.7150/jca.7402
74. Narayanan A, Söder B, Meurman J, et al. Composition of subgingival microbiota associated with periodontitis and diagnosis of malignancy-a cross-sectional study. Front Microbiol. 2023;14:1172340. doi:10.3389/fmicb.2023.1172340
75. Xia R, Jiang Z, Zhou Y, et al. Oral microbiota and gastric cancer: recent highlights and knowledge gaps. J Oral Microbiol. 2024;16(1):2391640. doi:10.1080/20002297.2024.2391640
76. Shi J, Feng J, Xie J, et al. Targeted blockade of TGF-β and IL-6/JAK2/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts. Sci Rep. 2017;7(1):8660. doi:10.1038/s41598-017-09020-8
77. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553-11572. doi:10.1007/s13277-016-5098-7
78. Masjedi A, Hashemi V, Hojjat-Farsangi M, et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 2018;108:1415-1424. doi:10.1016/j.biopha.2018.09.177
79. Loh KP, Consagra W, Magnuson A, et al. Associations of interleukin-6 with functional trajectories in older adults with cancer: Findings from the Health, Aging, and Body Composition Study. Exp Gerontol. 2023;177:112185. doi:10.1016/j.exger.2023.112185
80. Videmark AN, Christensen IJ, Feltoft CL, et al. Combined plasma C-reactive protein, interleukin 6 and YKL-40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer. Cancer Med. 2023;12(6):6675-6688. doi:10.1002/cam4.5455
81. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-248. doi:10.1038/nrclinonc.2018.8
82. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem. 2006;281(34):24171-24181. doi:10.1074/jbc.M604507200
83. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20(1):51-56. doi:10.1016/j.gde.2009.10.009
84. Britton WR, Cioffi I, Stonebraker C, et al. Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2024;16(17):3047. doi:10.3390/cancers16173047
85. Voll RM. EAV Discussions “The Basics”. Las Vegas, NV: VeraDyne Corporation; 2001 [updated 2001; cited 2025]. Accessed April 25, 2026. https://veradyne.net/eav_basics.html?utm_source=chatgpt.com.
86. Grigorova NP. Electro Acupuncture by Voll (EAV). Heliantheae; 2023 [updated 2023; cited 2025]. Accessed April 25, 2026. https://en.heliantheae.bg/electro-acupuncture-by-voll-eav-methodology/
87. Auffenberg C, Rosenthal LJ, Dresner N. Levamisole: a common cocaine adulterant with life-threatening side effects. Psychosomatics. 2013;54(6):590-593. doi:10.1016/j.psym.2013.02.012